Beximco Pharmaceuticals Limited (BXP) Rises 1.52% on Aug 1

August 1, 2017 - By Nellie Frank

Shares of Beximco Pharmaceuticals Limited (LON:BXP) last traded at 67, representing a move of 1.52%, or 1 per share, on volume of shares. After opening the trading day at 66, shares of Beximco Pharmaceuticals Limited traded in a close range. Beximco Pharmaceuticals Limited currently has a total float of 405.56M shares and on average sees 45,643 shares exchange hands each day. The stock now has a 52-week low of 28.75 and high of 71.75.

The Evolution Of The LSE In 200 Years

Trade and commerce in the UK can be traced back to hundreds of years ago. Today, it plays an important role in global trade and commerce as one of the biggest and most significant contributors.

It is undeniable that the UK is one of the most developed countries in the world as well. Because of this and its constant strive for progress, the global economy is continuously shaping up to become bigger and better through the years.

London Stock Exchange (LSE)

The LSE is the main stock exchange in the UK. It had been founded in 1801, making it one of the oldest stock exchanges in the world.

Today, the LSE is considered as the biggest stock exchange in Europe and the third biggest one in the world. As of the end of the third quarter, more than 2,290 companies are listed on the LSE, bringing its total market capitalization to more than ‘6 trillion.

Presently, the LSE Group (LSEG), which had been founded in October 2007 following the merger of the LSE and the Borsa Italiana, operates the LSE.

Financial Times Stock Exchange (FTSE) 100 Index

The FTSE 100 is the benchmark blue-chip index in the UK. It measures the top 100 companies listed on the LSE as a free-float, market-capitalization-weighted index. As of September, the FTSE 100 has a total market capitalization of ‘1.70 trillion.

The FTSE 100 had been founded on January 3, 1984 with a base value of 1,000 points. It is currently operated by the FTSE Group, a subsidiary of LSEG. Beximco Pharmaceuticals Limited is a stock traded on the U.K’s stock exchange.

Most of the components of the FTSE 100 are international companies, which is why it is not a strong indicator of the UK economy. Nonetheless, it is a strong indicator of the LSE, representing more than 80% of the total market capitalization on the LSE. The FTSE 250, which measures the top 250 companies listed on the LSE, is a stronger indicator of the UK economy than the FTSE 100 because of its broad nature and most of its components being domestic companies. Beximco Pharmaceuticals Limited has relatively good liquidity.

The FTSE 100 is rebalanced quarterly’ specifically every Wednesday immediately following the first Friday of March, June, September, and December. Components that have fallen short of the inclusion requirements are dropped to give way to those that have met all the said requirements.

The FTSE 100 had reached its all-time low of 427.50 points in February 1978; and its all-time high of 7,103.98 points in April 2015. Meanwhile, its best intraday high of 7,129 points had been reached on October 11.

Many investors are banking on the promising growth of the European economy. Amid the pressing concerns of today, it is still ideal for investors to penetrate European equity markets such as that of the UK.

Boasting with full potentials to realize its growth prospects, the UK economy guarantees meaningful investment returns for domestic and international investors alike. Those who still doubt this can simply look back through the hundreds of years that the UK economy had been tried and tested. Professional analysts might be interested how this will affect Beximco Pharmaceuticals Limited.

Beximco Pharmaceuticals Limited is engaged in the manufacturing and marketing of generic pharmaceuticals formulation products, including intravenous fluids and active pharmaceutical ingredients (APIs). The company has market cap of 49.11 billion GBP. The Firm also provides contract manufacturing services. It currently has negative earnings. The Firm produces approximately 300 generic medicines, which are available in over 500 different presentations and the portfolio encompasses various key therapeutic categories, including antibiotics, analgesics, anti-diabetic, respiratory, cardiovascular, central nervous system, dermatology and gastrointestinal.